ELOVL5 and breast cancer: After the confirmation of Elovl5 gene invalidation (Supplementary Fig. S2E, F), we found as expected that mammary tumor tissues from MMTV-PyMT;Elovl5−/− (hereafter termed Elovl5−/−) mice had a significantly increased in the percentage of C18:3 n-6 FA compared to mammary tumor tissues of MMTV-PyMT;Elovl5+/+ (hereafter termed Elovl5+/+) (Supplementary Fig. S2G).